Annovis Bio Enters Material Definitive Agreement
Ticker: ANVS · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $50,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Annovis Bio signed a big deal, details TBD.
AI Summary
Annovis Bio, Inc. announced on December 11, 2024, that it has entered into a material definitive agreement. The filing does not provide specific details about the agreement, its terms, or any associated financial figures.
Why It Matters
This filing indicates a significant new contract or partnership for Annovis Bio, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Annovis Bio, Inc.?
The filing does not specify the nature of the material definitive agreement.
When did Annovis Bio, Inc. enter into this material definitive agreement?
The earliest event reported is December 11, 2024.
Are there any financial terms disclosed in relation to this agreement?
No financial terms or amounts are disclosed in this filing.
What is the purpose of this Form 8-K filing?
The purpose is to report the entry into a Material Definitive Agreement and to file Financial Statements and Exhibits.
What is Annovis Bio, Inc.'s principal executive office address?
The principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Filing Stats: 1,001 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-12-11 06:10:36
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 ANVS New York Stock Exchange Item 1
- $50,000,000 — ng an aggregate offering price of up to $50,000,000 (the " Shares ") through Oppenheimer (t
Filing Documents
- tm2430444d2_8k.htm (8-K) — 28KB
- tm2430444d2_ex1-1.htm (EX-1.1) — 252KB
- tm2430444d2_ex5-1.htm (EX-5.1) — 10KB
- tm2430444d2_ex5-1img001.jpg (GRAPHIC) — 15KB
- 0001104659-24-127439.txt ( ) — 546KB
- anvs-20241211.xsd (EX-101.SCH) — 3KB
- anvs-20241211_lab.xml (EX-101.LAB) — 33KB
- anvs-20241211_pre.xml (EX-101.PRE) — 22KB
- tm2430444d2_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 11, 2024, Annovis Bio, Inc. (the " Company ") entered into an Equity Distribution Agreement (the " Distribution Agreement ") with Oppenheimer & Co. Inc., serving as agent (" Oppenheimer ") with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the " Common Stock "), having an aggregate offering price of up to $50,000,000 (the " Shares ") through Oppenheimer (the " Offering "). Any Shares offered and sold in the Offering will be issued pursuant to the Company's shelf Registration Statement on Form S-3 (File No. 333-276814) filed with the Securities and Exchange Commission (the " SEC ") on February1, 2024, which was declared effective on February 12, 2024, the related prospectus contained therein, and the prospectus supplement relating to the Offering to be filed with the SEC on December 11, 2024. Oppenheimer may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended (the " Securities Act "), including, without limitation, sales made through New York Stock Exchange (" NYSE ") or on any other existing trading market for the Common Stock. The Company has no obligation to sell any Shares and may at any time suspend offers under or terminate the Distribution Agreement in accordance with its terms. Oppenheimer will use commercially reasonable efforts to sell the Shares from time to time consistent with its normal sales practices and applicable federal rules, regulations and NYSE rules, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Oppenheimer a commission equal to 3.0% of the gross sales proceeds of any Shares sold through Oppenheimer under the Dist
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Distribution Agreement, dated December 11, 2024, by and between Annovis Bio, Inc. and Oppenheimer & Co. Inc. 5.1 Opinion of Loeb & Loeb LLP. 23.1 Consent of Loeb & Loeb LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Dated: December 11, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer